Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2023.11.028
- VernacularTitle:肝细胞癌靶向/免疫治疗效果的预测指标
- Author:
Pengwei REN
1
;
Ying HAN
1
;
Xinmin ZHOU
1
Author Information
1. Department of Gastroenterology， Xijing Hospital， Air Force Medical University， Xi’an 710032， China
- Publication Type:Review
- Keywords:
Carcinoma， Hepatocellular;
Drug Therapy;
Immunotherapy
- From:
Journal of Clinical Hepatology
2023;39(11):2705-2709
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma （HCC） is a common malignancy in China， and molecular-targeted drugs and immune checkpoint inhibitors for the treatment of advanced HCC are currently a research hotspot； however， there are large individual differences in the treatment outcome of advanced HCC. In order to further screen for the population with benefits from such treatment， predict treatment outcome， and improve disease prognosis， this article summarizes the studies on predicting the efficacy of targeted therapy/immunotherapy for HCC， so as to provide a reference for developing individualized treatment regimens for patients with advanced HCC.
